Table of Contents
Executive Summary — 7
SWOT
Analysis — 9
Turkey Pharmaceuticals And Healthcare
Industry SWOT — 9
Turkey Political
SWOT — 10
Turkey Economic SWOT — 10
Turkey Business Environment SWOT — 11
Pharmaceutical
Business Environment Rating — 12
Table: Emerging Europe
Pharmaceutical Business Environment Ratings (BER) for
Q409 — 12
Limits Of Potential
Returns — 13
Risks To Realisation Of
Returns — 13
Turkey – Market
Summary — 15
Regulatory Regime — 16
Intellectual Property Regime — 16
Intellectual Property
Shortcomings — 17
Counterfeit
Drugs — 18
Pricing Regime — 20
Table:
Turkish Pharmacy And Wholesale Mark-Ups — 20
Reimbursement
Regime — 21
Industry Trends and
Developments — 23
Epidemiology — 23
Table: Disease Burden In Emerging Europe — 24
Non-Communicable Diseases — 24
Communicable
Diseases — 25
Healthcare Sector — 25
Healthcare Expenditure — 26
Healthcare Sector
Reforms — 27
Health Insurance — 28
Private Healthcare Sector — 29
International
Co-operation — 30
Research And Development (R&D)
Sector — 30
Table: Turkey’s New R&D
Law — 31
Pharmaceutical Retail And
Distribution — 32
Medical Devices — 33
Recent Medical Devices Industry Developments — 35
Industry
Forecast Scenario — 36
Overall Market
Forecast — 36
Table: Turkey – Drug Expenditure
Indicators, Historical Data and Forecasts — 37
Key Growth
Factors – Industry — 38
Table: Turkey –
Healthcare Expenditure Indicators, Historical Data and
Forecasts — 39
Key Growth Factors –
Macroeconomic — 40
Table: Turkey - Economic Activity, 2006
– 2013 — 42
Prescription Market
Forecast — 43
Table: Turkey – Prescription Market
Indicators, Historical Data and Forecasts (TRYmn unless otherwise
stated) — 45
Patented Drug Market
Forecast — 46
Table: Turkey – Patented Market
Indicators, Historical Data and Forecasts — 46
Generic
Drug Market Forecast — 47
Table: Turkey – Generics
Market Indicators, Historical Data and Forecasts — 48
OTC
Market Forecast — 49
Table: Turkey – OTC Market
Indicators, Historical Data and Forecasts (TRYmn unless otherwise
stated) — 50
Medical Device Market
Forecast — 51
Table: Turkey Medical Device
Forecast — 51
Pharmaceutical Trade
Forecast — 52
Table: Turkey – Pharmaceutical Trade
Indicators, Historical Data and Forecasts (US$mn) — 53
Other Healthcare Data — 54
Table: Turkey – Other
Healthcare Indicators, Historical Data and Forecasts — 54
Competitive Landscape — 55
Pharmaceutical
Sector — 55
Table: Top 10 Pharmaceutical Companies In
Turkey By Market Share, MAT July 2008 — 56
Domestic
Industry — 56
Foreign Industry — 56
Recent Pharmaceutical Sector Developments — 57
Company
Profiles — 60
Novartis — 60
Sanofi-Aventis — 62
GlaxoSmithKline — 63
Pfizer — 64
Roche — 66
AstraZeneca — 68
Bayer — 69
Merck & Co — 71
Indigenous
Companies — 72
Abdi İbrahim — 72
Eczacibaşi Pharmaceuticals — 75
Sanovel
Pharmaceuticals — 78
EastPharma (formerly Deva
Holding) — 80
Actavis (formerly
Fako) — 83
Biomeks — 85
Country
Snapshot: Turkey Demographic Data — 86
Section 1:
Population — 86
Table: Demographic Indicators,
2005-2030 — 86
Table: Rural/Urban Breakdown,
2005-2030 — 87
Section 2: Education And
Healthcare — 87
Table: Education,
2002-2005 — 87
Table: Vital Statistics,
2005-2030 — 87
Section 3: Labour Market And Spending
Power — 88
Table: Employment Indicators,
2001-2006 — 88
Table: Consumer Expenditure, 2000-2012
(US$) — 88
BMI Methodology — 89
How We
Generate Our Pharmaceutical Industry Forecasts — 89
Pharmaceutical Business Environment Ratings
Methodology — 90
Ratings Overview — 90
Table: Pharmaceutical Business Environment Indicators — 91
Weighting — 92
Table: Weighting Of
Components — 92
Sources — 92
| 
View Cart
